INTERNATIONAL LIVER CANCER ASSOCIATION

International Liver Cancer Association 15th Annual Conference

 

September 2 - 5, 2021 Virtual Conference
Close
N. Poster
Poster title
Applicant name
Status
  P-01 Temporal and Spatial Dynamics of Hepatic Stellate Cell Activation in Intrahepatic Cholangiocarcinoma Liqin Zhu Received Received
  P-02 Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma Paula Restrepo Received Received
  P-03 Autoimmunity and cancer immunosurveillance in the biliary tree Jonathan Pol Received Received
  P-04 Inflamed class of HCC: an expansion of the immune class based upon new molecular features Josep M. Llovet Received Received
  P-05 Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. Petros Fessas Received Received
  P-06 New therapeutic targets in cisplatin-resistant hepatoblastoma Théo Hirsch Received Received
  P-07 Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma Katherine Lindblad Received Received
  P-09 Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the ectonucleotidase CD73 as a potential therapeutic target. Rosemary Faulkes Received Received
  P-10 Activating Mucosal-Associated Invariant T cells (MAITs) in vivo as a Novel Target for Liver Cancer Immunotherapy Benjamin Ruf Received Received
  P-11 The TUMOR SUPPRESOR ROLE OF THE a1-Na/K-ATPase/Src-p/PI3K SIGNALOSOME in NASH Related Hepatocellular Carcinoma: A TRANSLATIONAL STUDY. Juan Sanabria Received Received
  P-12 Interplay between EZH2 and OGT in hepatocellular carcinoma Margot Thirion Received Received
  P-14 Molecular characterization of HCC in Mongolia delineates unique genomic features Laura Torrens Received Received
  P-15 Exogenous Antioxidants, N-acetylcysteine and Glutathione, Enhance Cancer Initiation and Growth in Hepatocellular Carcinoma Vanilla Xin Zhang Received Received
  P-16 Dual mechanisms mediated by specific transcription factors and RalGAPA2 activates RalA signaling to support HCC development LU TIAN Received Received
  P-17 Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. David Pinato Received Received
  P-18 Portal vein thrombosis in HCC patients infected with COVID-19 Mohamed Elgazzar Received Received
  P-19 Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma Jordi Abril-Fornaguera Received Received
  P-20 Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver: A Spanish multicentre study Marta Romero-Gutiérrez Received Received
  P-21 PROGNOSIS OF PATIENTS WITH OTHER PRIMARY TUMORS ASSOCIATED TO HEPATOCELULLAR CARCINOMA. Miriam Celada Received Received
  P-22 Geographic, linguistic, and cultural factors are associated with clinical presentation, receipt of treatment, and survival of patients with hepatocellular carcinoma Belaynew Taye Received Received
  P-23 Hepatic elastometry and risk of recurrence after HCC resection PAULINE TORTAJADA Received Received
  P-24 Association of whole grains and dietary fiber intake with risk of liver cancer and chronic liver diseases in the NIH-AARP Diet and Health Study Xing Liu Received Received
  P-25 Gene Set adaptation through graph generation enhances signature discrimination power and validates metabolism-related prognostic signatures in Hepatocellular Carcinoma Josepmaria Argemi Received Received
  P-26 EXTERNAL VALIDATION OF THE INTEGRATED LIVER INFLAMMATORY SCORE (ILIS) AS A PROGNOSTIC INDEX IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Miriam Celada Received Received
  P-28 Undernutrition in patients with primary hepatocellular carcinoma Hitomi Takada Received Received
  P-29 Dual filtration system for isolation and single cell RNA sequencing of circulating tumor cells and clusters in hepatocellular carcinoma: a pilot study Vincent Chen Received Received
  P-30 The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. Ambreen Muhammed Received Received
  P-31 Clinicopathological characterization of steatohepatitic variant of hepatocellular carcinoma (SH-HCC). Loc TRAPANI Received Received
  P-34 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON Masatoshi Kudo Received Received
  P-35 The Efficacy and Prognostic Factors of TACE Combined with Apatinib in the Treatment of BCLC stage C Hepatocellular Carcinomas Weifu LV Received Received
  P-36 A Pilot Study of the combination of Immune Checkpoint Inhibition with Ablation in Subjects with Hepatocellular Carcinoma; an evaluation of Trans-arterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) Rebecca Wetzel Received Received
  P-37 A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. Thomas Talbot Received Received
  P-38 Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma Thi Thu Nga Nguyen Received Received
  P-41 Early antibiotic exposure is not detrimental to response to immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study. Petros Fessas Received Received
  P-42 Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial Stephen Lam CHAN Received Received
  P-43 The Number of Small Hepatocellular Carcinoma Nodules in Patients Listed for Liver Transplantation within the Alpha-Fetoprotein Score Is a Prognostic Risk Factor Alina Pascale Received Received
  P-45 Real-world outcomes of patients with hepatocellular carcinoma treated with transarterial radioembolization: results from CIRT, a large European prospective multi-centre observational study Frank Kolligs Received Received
  P-46 Exploratory Network Meta-analyses of Selective Internal Radiation Therapy versus Sorafenib, Lenvatinib, and Atezolizumab-Bevacizumab as First-line Treatment in Subgroups of Patients with Hepatocellular Carcinoma Richard Pollock Received Received
  P-47 Previous/Concurrent Radiation Enhanced the Efficacy of Immunotherapy in Metastatic and Recurrent Liver Cancer: A Pilot Study from the Real-world Data Bo Chen Received Received
  P-48 Progression patterns and clinical outcomes following immune checkpoint inhibition for hepatocellular carcinoma (HCC): a multi-institutional international study. Thomas Talbot Received Received
  P-49 Identification of Regorafenib Prognostic index (REP index) via recursive partitioning analysis in Advanced Hepatocellular Carcinoma Patients Receiving systemic treatment. margherita rimini Received Received
  P-50 Impact of previous surgery on prognosis in patients with cholangiocarcinoma under chemotherapy margherita rimini Received Received
  P-51 Free Androgen Index Levels May Influence the Trans-arterial Chemoembolization with Doxorubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results. Silvia Acosta-Lopez Received Received
  P-53 A humanized Claudin-1-specific monoclonal antibody for treatment of hepatocellular carcinoma Marion Muller Received Received
  P-54 Emerging role of circulating miR-23b-3p and tissue miR-193a-3p as potential innovative biomarkers for human hepatocellular carcinoma. Ilaria Grossi Received Received
  P-55 Lifestyle changes in DAA-cured Hepatitis C patients with advanced liver disease included in a nurse-led liver cancer screening program Gemma Iserte Received Received
  P-57 Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters. Sergio Muñoz-Martínez Received Received
  P-58 Deciphering Liver Cancer Tissue Organization by 3D Electron Microscopy and machine learning Christophe Grosset Received Received
  P-59 Low baseline plasma L-Glutamine concentration identifies hepatocellular carcinoma patients at high risk of developing early gastrointestinal adverse events during sorafenib treatment. Loreto Boix Received Received
  P-60 Efficacy and Safety of Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Retrospective Analysis KyungHye Bang Received Received
  P-61 Novel management score of systemic therapy for hepatocellular carcinoma patients Issei SAEKI Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
01:51
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

International Liver Cancer Association 15th Annual Conference

 

September 2 - 5, 2021 Virtual Conference
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 19/08/2021 TO 02/09/2022
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert